Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Debunking Myths in the US Healthcare System
Top Ten Searches
gynecomastia empyema henoch–schönlein otitis media dyspnea jaundice ventricle lyme immunodeficiency coolingYour Article Summary
Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia
Cancer, 06/24/09
Renneville A et al. - In a study to determine whether WT1 mutations are a predictor of poor outcome in pts with acute myeloid leukemia (AML), it was reported that WT1 mutations represent an adverse prognostic factor in young adults with AML. Prospective trials should confirm the clinical relevance of WT1 mutations in relation to other prognostic factors in pts with AML.
Methods- 268 young adults (ages 15-50 yrs) with AML who were treated on the Acute Leukemia French Association 9802 trial were studied.
- WT1 exon 7 and 9 mutations were screened retrospectively by polymerase chain reaction and direct sequencing.
- Pts were assessed for presence of the fms-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD), FLT3-D835/I836, nucleophosmin 1 (NPM1), and CCAAT/enhancer binding protein α (CEBPA) mutations.
- WT1 mutations were identified in 14 pts (5%) and were associated with a younger age and an FLT3-ITD.
- No mutation was detected in pts who had favorable cytogenetics.
- Pts who had WT1 mutations had a shorter overall survival at 4 yrs (22% vs 56%) and a higher risk of recurrence at 4 yrs (82% vs 46%) vs pts who had wild-type WT1.
- Within the subgroup of pts who had normal karyotype AML (n=106), WT1 mutation was identified as an independent adverse prognostic factor for risk of recurrence.
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Detection of Cytomegalovirus DNA in Dried Blood Spots of Minnesota Infants Who Do Not Pass Newborn Hearing Screening
The Pediatric Infectious Disease Journal, 10/14/09
Genetics of food allergy
Current Opinion in Pediatrics, 10/23/09
Genetic forms of hypopituitarism and their manifestation in the neonatal period
Early Human Development, 10/30/09
Today in Pediatric Heme/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: A therapeutic advances in Childhood Leukemia Consortium Study
Journal of Clinical Oncology, 10/22/09
Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia
Journal of Clinical Oncology, 11/09/09
Medulloblastoma in childhood: revisiting intrathecal therapy in infants and children
Cancer Chemotherapy and Pharmacology, 10/29/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


